{"title": "Amgen's Lumakras is set to make a splash, but long-term success might be elusive: analyst", "author": "Kevin Dunleavy", "url": "https://www.fiercepharma.com/pharma/amgen-s-lumakras-set-to-make-a-splash-but-long-term-success-might-be-elusive-analysis", "hostname": "fiercepharma.com", "description": "As the first treatment to crack the elusive KRAS mutation of non-small cell lung cancer, the arrival of Amgen's Lumakras has been anxiously anticipated. | With much anticipation, Amgen is racing Lumakras toward the market. But Bernstein analyst Ronny Gal warns investors that the cancer treatment may have difficulty sustaining its success in long term.", "sitename": "FiercePharma", "date": "2021-05-26", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}